Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 5/20 | 0.72 |
| ▸ | DHCR7 | Q9UBM7 | 5/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20993846 | 0.89 | EBP (0.70) | EBPDHCR7NPSR1EPHX2KMT2A | |
| SCHEMBL17007404 | 0.85 | EBP (0.66) | EBPDHCR7NPSR1LMNAEPHX2 | |
| SCHEMBL17007433 | 0.84 | DHCR7 (1.00) | EBPDHCR7NPSR1EPHX2KMT2A | |
| SCHEMBL17007461 | 0.84 | EBP (0.97) | EBPDHCR7NPSR1EPHX2ALDH1A1 | |
| SCHEMBL17007407 | 0.83 | EBP (0.74) | EBPDHCR7NPSR1EPHX2KMT2A | |
| Hydrochloric Acid SCHEMBL17007426 | 0.83 | DHCR7 (0.97) | EBPDHCR7NPSR1EPHX2KMT2A | |
| SCHEMBL22032981 | 0.83 | EBP (0.78) | EBPDHCR7NPSR1EPHX2ALDH1A1 | |
| SCHEMBL17007504 | 0.82 | EBP (1.00) | EBPDHCR7NPSR1EPHX2ALDH1A1 | |
| SCHEMBL17007435 | 0.82 | EBP (1.00) | EBPDHCR7NPSR1EPHX2ALDH1A1 | |
| SCHEMBL17007476 | 0.81 | EBP (0.77) | EBPDHCR7NPSR1EPHX2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856233-B2 | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160313302-A1 | TARGETING EMOPAMIL BINDING PROTEIN (EBP) WITH SMALL MOLECULES THAT INDUCE AN ABNORMAL FEEDBACK RESPONSE BY LOWERING ENDOGENOUS CHOLESTEROL BIOSYNTHESIS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160313302-A1 | TARGETING EMOPAMIL BINDING PROTEIN (EBP) WITH SMALL MOLECULES THAT INDUCE AN ABNORMAL FEEDBACK RESPONSE BY LOWERING ENDOGENOUS CHOLESTEROL BIOSYNTHESIS | SREBF1, SREBF2, EBPL | EBP 4/4885DHCR7 54/4885NPSR1 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.